APL-1401

N/A

Report date: 2023/08/29 15:12:46
NME

Base Information

Drug NameAPL-1401
Drug Alias NameAPL-1401
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine beta-hydroxylase inhibitors
TargetsDopamine beta-hydroxylase
Therapy Area/IndicationsAutoimmune DiseasesColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAsieris Pharmaceuticals Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Inactive CompaniesN/A
Active IndicationsColitis, Ulcerative
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A